Madrigal Q3 cash $153.2M; MAESTRO-NASH topline data on track for Q4 2022

MADRIGAL PHARMACEUTICALS, INC.

Cash, equivalents and marketable securities $153.2M at Sep 30, 2022, down from $270.3M at Dec 31, 2021.
R&D expenses $68.3M for Q3 2022 vs $54.9M in Q3 2021; G&A $12.1M vs $8.3M.
Cash used in operations for nine months ended Sep 30, 2022 was $166.3M.
Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned H1 2023.
Two resmetirom oral abstracts accepted at AASLD Liver Meeting presenting cirrhosis and noninvasive data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.